Relmada Therapeutics 2023 EPS $(3.28)
Portfolio Pulse from Benzinga Newsdesk
Relmada Therapeutics reported its 2023 earnings per share (EPS) at $(3.28), indicating a loss per share for the year.

March 19, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Relmada Therapeutics reported a loss of $(3.28) per share for 2023, which may concern investors about the company's profitability.
A negative EPS typically indicates that the company is not currently profitable, which can lead to negative investor sentiment and potentially lower stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100